These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22327124)

  • 1. A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.
    Ishiguro M; Watanabe T; Yamaguchi K; Satoh T; Ito H; Seriu T; Sakata Y; Sugihara K
    Jpn J Clin Oncol; 2012 Apr; 42(4):287-94. PubMed ID: 22327124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.
    Boku N; Sugihara K; Kitagawa Y; Hatake K; Gemma A; Yamazaki N; Muro K; Hamaguchi T; Yoshino T; Yana I; Ueno H; Ohtsu A
    Jpn J Clin Oncol; 2014 Mar; 44(3):214-23. PubMed ID: 24526771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.
    Yamaguchi K; Watanabe T; Satoh T; Ishiguro M; Izawa M; Inoshiri S; Sugihara K; Sakata Y
    Jpn J Clin Oncol; 2014 Jun; 44(6):541-6. PubMed ID: 24771864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
    Price TJ; Peeters M; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Zhang K; Murugappan S; Sidhu R
    Lancet Oncol; 2014 May; 15(6):569-79. PubMed ID: 24739896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
    Cartwright TH; Genther R
    Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A postmarketing surveillance study on erbitux (cetuximab) in patients with metastatic colorectal cancer refractory to irinotecan-containing treatment.
    Huang WT; Chen HH; Yeh CH; Lu YC; Hwang WS; Huang JS; Chen CP; Lin PC; Uen WC; Lee YC; Wang HM; Wu HC; Chen JS; Kao RH; Huang CC; Jeng HH; Lin CJ; Hsieh RK
    J Investig Med; 2013 Oct; 61(7):1108-14. PubMed ID: 24013526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
    Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
    Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Muro K
    Int J Clin Oncol; 2011 Aug; 16(4):416-20. PubMed ID: 21437572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer.
    Steele N; Anthony A; Saunders M; Esmarck B; Ehrnrooth E; Kristjansen PE; Nihlén A; Hansen LT; Cassidy J
    Br J Cancer; 2012 Feb; 106(5):793-8. PubMed ID: 22315057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.